Discrepancy between left ventricular hypertrophy by echocardiography and electrocardiographic hypertrophy: clinical characteristics and outcomes.
diagnostic imaging
echocardiography
electrocardiography
Journal
Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
23
06
2021
accepted:
07
09
2021
entrez:
24
9
2021
pubmed:
25
9
2021
medline:
22
12
2021
Statut:
ppublish
Résumé
The clinical significance of the discrepancy between left ventricular hypertrophy (LVH) by echocardiography and ECG remains to be elucidated. After excluding patients who presented with pacemaker placement, QRS duration ≥120 ms and cardiomyopathy and moderate to severe valvular disease, we retrospectively analysed 3212 patients who had undergone both scheduled transthoracic echocardiography (echo) and ECG in a hospital-based population. Cornell product >2440 mm · ms was defined as ECG-based LVH; left ventricular mass index >115 g/m The cumulative 3-year incidences of a composite of all-cause death and major adverse cardiovascular events were 32.0%, 33.8%, 19.2% and 15.7%, respectively. After adjusting for confounders, the HRs relative to that in no LVH were 1.63 (95% CI 1.16 to 2.28), 1.68 (95% CI 1.23 to 2.30) and 1.09 (95% CI 0.85 to 1.41) in patients with both ECG-based and echo-based LVH, those with only echo-based LVH, and those with only ECG-based LVH, respectively. Echo-based LVH without ECG-based LVH was associated with a significant risk of adverse clinical events, and the risk was comparable to that in patients with both echo-based and ECG-based LVH.
Sections du résumé
BACKGROUND
The clinical significance of the discrepancy between left ventricular hypertrophy (LVH) by echocardiography and ECG remains to be elucidated.
METHODS
After excluding patients who presented with pacemaker placement, QRS duration ≥120 ms and cardiomyopathy and moderate to severe valvular disease, we retrospectively analysed 3212 patients who had undergone both scheduled transthoracic echocardiography (echo) and ECG in a hospital-based population. Cornell product >2440 mm · ms was defined as ECG-based LVH; left ventricular mass index >115 g/m
RESULTS
The cumulative 3-year incidences of a composite of all-cause death and major adverse cardiovascular events were 32.0%, 33.8%, 19.2% and 15.7%, respectively. After adjusting for confounders, the HRs relative to that in no LVH were 1.63 (95% CI 1.16 to 2.28), 1.68 (95% CI 1.23 to 2.30) and 1.09 (95% CI 0.85 to 1.41) in patients with both ECG-based and echo-based LVH, those with only echo-based LVH, and those with only ECG-based LVH, respectively.
CONCLUSIONS
Echo-based LVH without ECG-based LVH was associated with a significant risk of adverse clinical events, and the risk was comparable to that in patients with both echo-based and ECG-based LVH.
Identifiants
pubmed: 34556560
pii: openhrt-2021-001765
doi: 10.1136/openhrt-2021-001765
pmc: PMC8461736
pii:
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
J Am Coll Cardiol. 1992 Nov 1;20(5):1180-6
pubmed: 1401620
Am J Cardiol. 2015 Feb 15;115(4):515-22
pubmed: 25542394
J Am Coll Cardiol. 1995 Feb;25(2):417-23
pubmed: 7829796
Circulation. 2009 Mar 17;119(10):e251-61
pubmed: 19228820
J Emerg Med. 1990 Sep-Oct;8(5):607-15
pubmed: 2254610
Cardiovasc Diagn Ther. 2017 Jun;7(3):244-251
pubmed: 28567350
Heart Vessels. 2020 Feb;35(2):223-231
pubmed: 31297639
BMJ Open. 2019 Nov 21;9(11):e032663
pubmed: 31753896
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
J Am Coll Cardiol. 2008 Dec 16;52(25):2148-55
pubmed: 19095132
Am Heart J. 2010 Apr;159(4):652-8
pubmed: 20362725
Sci Rep. 2018 Apr 23;8(1):6366
pubmed: 29686287
J Electrocardiol. 2008 Nov-Dec;41(6):498-500
pubmed: 18804788
JAMA. 2006 Sep 13;296(10):1242-8
pubmed: 16968848
J Am Heart Assoc. 2017 Jan 22;6(1):
pubmed: 28111363
Circ J. 2014;78(2):465-75
pubmed: 24284883
Am Heart J. 2005 Jul;150(1):161-7
pubmed: 16084164
Circ J. 2007 May;71(5):731-5
pubmed: 17457000
Open Heart. 2017 Mar 22;4(1):e000552
pubmed: 28533915
Circulation. 2001 May 15;103(19):2346-51
pubmed: 11352882
J Electrocardiol. 2014 Sep-Oct;47(5):649-54
pubmed: 25012077
Circ Rep. 2019 Dec 3;1(12):617-622
pubmed: 33693108
Eur Heart J. 2008 Mar;29(6):741-7
pubmed: 18204091
Hypertension. 2019 Dec;74(6):1357-1365
pubmed: 31679419
Circ J. 2019 Feb 25;83(3):604-613
pubmed: 30700662
PLoS One. 2018 Aug 30;13(8):e0203227
pubmed: 30161243
J Am Heart Assoc. 2019 Mar 5;8(5):e009959
pubmed: 30827132
J Electrocardiol. 2013 Nov-Dec;46(6):497-504
pubmed: 24075126
Clin Cardiol. 2018 Sep;41(9):1246-1251
pubmed: 30062778
J Am Coll Cardiol. 1984 Jul;4(1):17-27
pubmed: 6736444
J Hypertens. 2014 Dec;32(12):2472-8; discussion 2478
pubmed: 25340854
J Electrocardiol. 2010 May-Jun;43(3):200-8
pubmed: 19709670